Preventing cytokine storm syndrome in COVID-19 using α-1 adrenergic receptor antagonists

Maximilian F. Konig, Mike Powell, Verena Staedtke, Ren Yuan Bai, David L. Thomas, Nicole Fischer, Sakibul Huq, Adham M. Khalafallah, Allison Koenecke, Ruoxuan Xiong, Brett Mensh, Nickolas Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein, Joshua T. Vogelstein, Susan Athey, Shibin Zhou, Chetan Bettegowda

Research output: Contribution to journalReview articlepeer-review

Abstract

Dysregulated host immune responses drive mortality in pneumonia and acute respiratory distress syndrome (ARDS) caused by a wide range of infections. In coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits an exuberant local or systemic immune response (hyperinflammation) in the lung and other sites of viral replication, compromising organ function and leading to high morbidity and mortality (1-4).

Original languageEnglish (US)
Pages (from-to)3345-3347
Number of pages3
JournalJournal of Clinical Investigation
Volume130
Issue number7
DOIs
StatePublished - Jul 1 2020

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Preventing cytokine storm syndrome in COVID-19 using α-1 adrenergic receptor antagonists'. Together they form a unique fingerprint.

Cite this